NBP.US NovaBridge Biosciences
- Market cap
- USD 98.6M
- P/E
- -
- P/B
- 0.49x
- ROE
- -37.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is NBP.US undervalued?
Graham numberThe Graham number of NovaBridge Biosciences cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
NovaBridge Biosciences fundamental analysis
No fundamental analysis for NovaBridge Biosciences yet.
NovaBridge Biosciences stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About NovaBridge Biosciences
NovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology. Its product pipeline comprises givastomig, a potential CLDN18.2 bispecific antibody, which is in phase 2 clinical trial combination with nivolumab and chemotherapy for the treatment of gastric cancer and other CLDN18.2-positive gastrointestina…
Full company profileNovaBridge Biosciences financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
NovaBridge Biosciences annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 11.3M | 53.8M | 30.0M | 1.54B | 88.0M | -10.7M | 4.49M | 0.00 | 0.00 | - |
| Gross Profit | 11.6M | 53.8M | 30.0M | 1.54B | 41.6M | -10.7M | 4.49M | - | -858K | - |
| Operating Income | -274M | -456M | -1.46B | 156M | -2.07B | -366M | -511M | -375M | -94.3M | -81.3M |
| EBITDA | -279M | -432M | -192M | 179M | -2.04B | -357M | -340M | -368M | -88.3M | -75.4M |
| Net Income | -298M | -403M | -1.45B | 471M | -2.33B | -968M | -1.47B | -162M | -46.3M | -75.6M |
| EPS | -5.13 | -6.92 | -25 | 6.89 | -31 | -12 | -18 | -2.00 | -1.11 | -0.65 |
| Balance Sheet | ||||||||||
| Total Assets | 1.03B | 2.38B | 1.74B | 6.33B | 879M | 4.07B | 369M | 1.55B | 261M | 232M |
| Total Liabilities | 1.33B | 3.33B | 3.77B | 712M | 163M | 1.07B | 126M | 84.1M | 29.6M | 30.4M |
| Shareholders' Equity | 410M | -955M | 1.07B | 5.63B | 715M | 3.01B | 243M | 1.47B | 231M | 201M |
| Cash & Short-term Investments | 574M | 1.84B | 1.17B | 4.79B | 671M | 3.45B | 312M | 1.27B | 211M | 191M |
| Total Debt | 213M | 147M | 132M | 19.1M | 17.6M | 38.3M | 3.89M | 28.3M | 3.07M | 4.46M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -252M | -281M | -868M | 434M | -973M | -1.10B | -72.9M | -384M | -20.6M | -65.7M |
| Capital Expenditure | 20.3M | 14.4M | 12.2M | 8.01M | 29.9M | 45.8M | 164K | 350K | 7.00K | 1.98M |
| Free Cash Flow | -272M | -295M | -880M | 426M | -1.00B | -1.15B | -73.0M | -385M | -20.6M | -67.7M |
| Ratios | ||||||||||
| ROE | -72.7% | - | -135.4% | 8.4% | -325.9% | -32.2% | -604.2% | -11.1% | -20.0% | -37.6% |
| ROA | -29.1% | -17.0% | -83.3% | 7.4% | -265.3% | -23.8% | -397.3% | -10.5% | -17.8% | -32.6% |
| Net Profit Margin | -2,647.4% | -749.0% | -4,826.8% | 30.5% | -2,648.7% | - | -32,674.0% | - | - | - |
| Debt to Equity | 0.52x | - | 0.12x | 0.00x | 0.02x | 0.01x | 0.02x | 0.02x | 0.01x | 0.02x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
NovaBridge Biosciences dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | CNY 5.28M | 0.09 | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns NovaBridge Biosciences
- Insiders 15.71%
- Institutions 30.71%
- Public & others 53.57%
- Shares outstanding 116M
- Free float 70.4M
Top funds holding NBP.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Belfius Equities Cure C Cap | 1.13M | 0.98% | 0.00% | Apr 2026 |
| iShares Biotechnology ETF | 653K | 0.56% | -0.19% | Oct 2026 |
| E Fund Global Medi Inds Allc QDII CNY A | 589K | 0.51% | -42.86% | Jun 2026 |
| OAKS Emerg and Frntr Opp A EUR Acc Ser 4 | 316K | 0.27% | +0.04% | Jul 2026 |
| State Street® SPDR® Portfolio EM ETF | 293K | 0.25% | 0.00% | Oct 2026 |
| Taikang Kaitai China New Opp I HKD Acc | 171K | 0.15% | +32.75% | Jun 2026 |
| ALPS Medical Breakthroughs ETF | 139K | 0.12% | 0.00% | Oct 2026 |
| iShares Nasdaq US Biotech ETF USD Acc | 100K | 0.09% | +0.21% | Oct 2026 |
| Invesco NASDAQ Future Gen 200 ETF | 64.6K | 0.06% | +1.92% | Oct 2026 |
| Fidelity Nasdaq Composite Index | 44.1K | 0.04% | -35.91% | Aug 2026 |
| Acadian Select Em Mkts Equity A GBP Acc | 27.9K | 0.02% | 0.00% | Oct 2026 |
| China Universal NASDAQ Bio-Tch ETF(QDII) | 17.9K | 0.02% | +5.45% | Jun 2026 |
| State Street® SPDR® S&P® China ETF | 14.9K | 0.01% | 0.00% | Oct 2026 |
| Dimensional World Equity GBP Acc | 11.0K | 0.01% | -0.22% | Sep 2026 |
| Dimensional World Allc 60/40 GBP Acc | 9.34K | 0.01% | 0.00% | Sep 2026 |
| Invesco Nasdaq Biotechnology ETF | 8.55K | 0.01% | 0.00% | Oct 2026 |
| ProShares Ultra Nasdaq Biotechnology | 4.48K | 0.00% | 0.00% | Oct 2026 |
| GF NASDAQ Bio-Tech Idx QDII USD A | 2.38K | 0.00% | +16.41% | Jun 2026 |
| Dimensional EM Cor Eq LC ESG Sc USD A | 1.40K | 0.00% | -0.29% | Sep 2026 |
| DFA International Core Equity Class F | 1.36K | 0.00% | 0.00% | Aug 2026 |
Top institutions holding NBP.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Hillhouse Capital Advisors, Ltd. | 5.98M | 5.16% | 0.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 3.65M | 3.15% | -4.82% | Jun 2026 |
| AIHC Capital Management Limited | 2.88M | 2.48% | +27.18% | Jun 2026 |
| Siren, L.L.C. | 2.00M | 1.73% | -33.18% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 1.23M | 1.06% | 0.00% | Jun 2026 |
| Candriam Luxembourg S.C.A. | 1.13M | 0.98% | 0.00% | Jun 2026 |
| Adage Capital Partners Gp LLC | 1.00M | 0.86% | 0.00% | Jun 2026 |
| Two Sigma Investments LLC | 851K | 0.73% | 0.00% | Jun 2026 |
| BlackRock Inc | 686K | 0.59% | +9.36% | Jun 2026 |
| Citadel Advisors Llc | 623K | 0.54% | +273.81% | Jun 2026 |
| E Fund Management Co., Ltd. | 589K | 0.51% | 0.00% | Jun 2026 |
| Exome Asset Management LLC | 577K | 0.50% | 0.00% | Jun 2026 |
| Renaissance Technologies Corp | 485K | 0.42% | -36.01% | Sep 2026 |
| State Street Corp | 360K | 0.31% | -2.63% | Jun 2026 |
| Woodline Partners LP | 350K | 0.30% | -50.00% | Jun 2026 |
| Fiera Capital Corporation | 316K | 0.27% | 0.00% | Jun 2026 |
| UBS Group AG | 302K | 0.26% | +374.94% | Jun 2026 |
| Barclays PLC | 279K | 0.24% | -6.78% | Jun 2026 |
| The Goldman Sachs Group Inc | 161K | 0.14% | +43.44% | Jun 2026 |
| ALPS Advisors Inc | 117K | 0.10% | 0.00% | Jun 2026 |
NovaBridge Biosciences company profile
- Company name
- NovaBridge Biosciences
- Ticker
- NBP.US
- Exchange
- USA Stocks
- Listed since
- Jan 17, 2020
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 30
- Fiscal year end
- December
- Address
- 2440 Research Boulevard, Rockville, MD, United States, 20850
- Phone
- 240 745 6330
- Website
- novabridge.com
About NovaBridge Biosciences
NovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology. Its product pipeline comprises givastomig, a potential CLDN18.2 bispecific antibody, which is in phase 2 clinical trial combination with nivolumab and chemotherapy for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies; Phase 1b clinical trial in combination with nivolumab and chemotherapy in first-line gastric cancer. The company also develops VIS-101, VEGF-A × ANG-2 bispecific biologics in Phase 2 clinical trial to treat wet age-related macular degeneration and other retinal diseases, including diabetic macular edema; ragistomag, which is in Phase 1clinical trial for multiple solid tumors. It has a licensing agreement with AskGene to develop and commercialize VIS-101; collaborations with Bristol Myers Squibb for the development of givastomig; and license and collaboration agreement with AbbVie Ireland Unlimited Company for the development and commercialization of lemzoparlimab. The company was formerly known as I-Mab and change its name to NovaBridge Biosciences in October 2025. NovaBridge Biosciences was founded in 2014 and is headquartered in Rockville, Maryland.
NovaBridge Biosciences management
9- Mr. Wei FuExecutive Chairman · born 1982
- Mr. Sean Wuxiong Cao M.B.A., Ph.D.Chief Business Development Officer & Director · born 1967
- Dr. Srishti Gupta M.D.CEO & Director · born 1976
- Mr. Mark HaglerPresident & Chief Commercial Officer
- Dr. Charles Silberstein CFA, M.B.A., M.D.Chief Financial Officer · born 1971
- Mr. Tyler EhlerSenior Director of Investor Relations
- Ms. Liwei LinGeneral Counsel & Board Secretary · born 1988
- Dr. Cong Xu M.D., Ph.D.Executive VP and Head of R&D Center of Excellence · born 1985
- Dr. Phillip Dennis M.D., Ph.D.Chief Medical Officer · born 1963